Blog
22 Articles
Platform Trial Increases Efficiency in Studying Immunotherapy
Dr. Elizabeth Jaffee is betting that three types of immunotherapy will rev up the immune system and make chemotherapy more effective in a platform trial.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
A New Immunotherapy Combination for Metastatic Pancreatic Cancer
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Claudin May Be the Next Big Target in Pancreatic Cancer Treatment
Dr. Wungki Park leads a trial that uses a monoclonal antibody to target a protein that is common in pancreatic cancer.
Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Combining Two Drugs with Different Approaches to Enhance Treatment
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
Testing the Safety of an Immunotherapy Combination After Surgery
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine plus chemotherapy after surgery to remove pancreatic cancer.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Aiming to Improve Immunotherapy for Pancreatic Cancer
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
Immunotherapy Combination Plus Radiation for Pancreatic Cancer
Researchers are testing two monoclonal antibodies approved to treat melanoma plus radiation as a treatment for pancreatic cancer.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.